Coherus BioSciences, Inc.

Historical 13F Holders

Symbol
CHRS
CUSIP
19249H103
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 19249H103 since 12/18/2024, largest first.

Filer % of Class Filed
Timothy G. Youngquist 2020 Irrevocable Trust 13G/A 8.3% 5/15/2026
Event 3/31/2026
Bering Partners II, L.P. 13G
6.5% 11/4/2025
Event 9/5/2025
BlackRock, Inc. 13G 5.8% 7/27/2026
Event 6/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (3)
Thomas A. Satterfield, Jr. 13G/A 4.6% 4/29/2026
Event 3/31/2026
Rubric Capital Management LP 13G/A
4.6% 2/13/2025
Event 12/31/2024
Vanguard Group Inc 13G/A 0% 3/26/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 12 13.2 M $16.0 M
2026 Q2 152 70.4 M $100 M
2026 Q1 163 71.6 M $121 M
2025 Q4 133 57.3 M $81.3 M
2025 Q3 121 51.7 M $84.8 M
2025 Q2 118 55.6 M $40.6 M
2025 Q1 123 62.0 M $50.0 M
2024 Q4 132 65.7 M $90.6 M
2024 Q3 135 77.4 M $126 M
2024 Q2 145 84.5 M $146 M
2024 Q1 153 88.4 M $212 M
2023 Q4 170 85.6 M $283 M
2023 Q3 181 94.1 M $349 M
2023 Q2 172 86.8 M $371 M
2023 Q1 173 78.6 M $538 M
2022 Q4 176 85.5 M $677 M
2022 Q3 180 77.7 M $746 M
2022 Q2 182 78.9 M $572 M
2022 Q1 187 76.1 M $981 M
2021 Q4 212 82.4 M $1.32 B
2021 Q3 196 76.1 M $1.22 B
2021 Q2 203 82.6 M $1.14 B
2021 Q1 218 85.0 M $1.24 B
2020 Q4 206 86.9 M $1.51 B
2020 Q3 213 88.2 M $1.62 B
2020 Q2 201 86.8 M $1.55 B
2020 Q1 199 74.7 M $1.21 B
2019 Q4 201 73.7 M $1.33 B
2019 Q3 181 69.4 M $1.41 B
2019 Q2 163 67.8 M $1.50 B
2019 Q1 123 68.8 M $938 M
2018 Q4 120 66.3 M $600 M
2018 Q3 124 67.6 M $1.12 B
2018 Q2 133 66.1 M $926 M
2018 Q1 112 56.0 M $619 M
2017 Q4 104 49.5 M $436 M
2017 Q3 106 47.0 M $628 M
2017 Q2 123 40.1 M $576 M
2017 Q1 122 37.6 M $795 M
2016 Q4 133 30.1 M $848 M
2016 Q3 126 28.1 M $754 M
2016 Q2 90 25.4 M $429 M
2016 Q1 76 18.2 M $387 M
2015 Q4 82 16.7 M $384 M
2015 Q3 81 16.2 M $334 M
2015 Q2 76 15.1 M $434 M
2015 Q1 53 7.27 M $222 M
2014 Q4 39 9.87 M $158 M